TY - JOUR
T1 - Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the european prospective investigation into cancer and nutrition
AU - Allen, Naomi E.
AU - Tsilidis, Konstantinos K.
AU - Key, Timothy J.
AU - Dossus, Laure
AU - Kaaks, Rudolf
AU - Lund, Eiliv
AU - Bakken, Kjersti
AU - Gavrilyuk, Oxana
AU - Overvad, Kim
AU - Tjønneland, Anne
AU - Olsen, Anja
AU - Fournier, Agnès
AU - Fabre, Alban
AU - Francxoise, Clavel Chapelon
AU - Nathalie, Chabbert Buffet
AU - Sacerdote, Carlotta
AU - Krogh, Vittorio
AU - Bendinelli, Benedetta
AU - Tumino, Rosario
AU - Panico, Salvatore
AU - Bergmann, Manuela
AU - Schuetze, Madlen
AU - Duijnhoven, Fränzel J.B.Van
AU - Bas, H. Bueno De Mesquita
AU - Charlotte, N. Onland Moret
AU - Gils, Carla H.Van
AU - Amiano, Pilar
AU - Barricarte, Aurelio
AU - Chirlaque, Maria Dolores
AU - Molina-Montes, Maria Esther
AU - Redondo, María Luisa
AU - Duell, Eric J.
AU - Khaw, Kay Tee
AU - Wareham, Nick
AU - Rinaldi, Sabina
AU - Fedirko, Veronika
AU - Mouw, Traci
AU - Michaud, Dominique S.
AU - Riboli, Elio
PY - 2010/12/15
Y1 - 2010/12/15
N2 - Estrogen-only menopausal hormone therapy (HT increases the risk of endometrial cancer, but less is known about the association with other types of HT. Using Cox proportional hazards regression, the authors examined the association of various types of HT with the risk of endometrial cancer among 115,474 postmenopausal women recruited into the European Prospective Investigation into Cancer and Nutrition between 1992 and 2000. After a mean follow-up period of 9 years, 601 incident cases of endometrial cancer were identified. In comparison with never users of HT, risk of endometrial cancer was increased among current users of estrogen-only HT (hazard ratio (HR = 2.52, 95% confidence interval (CI): 1.77, 3.57), tibolone (HR = 2.96, 95% CI: 1.67, 5.26), and, to a lesser extent, estrogen-plus-progestin HT (HR = 1.41, 95% CI: 1.08, 1.83), although risks differed according to regimen and type of progestin constituent. The association of HT use with risk was stronger among women who were older, leaner, or had ever smoked cigarettes. The finding of a strong increased risk of endometrial cancer with estrogenonly HT and a weaker association with combined HT supports the hypothesis that progestins have an attenuating effect on endometrial cancer risk. The increased risk associated with tibolone use requires further investigation.
AB - Estrogen-only menopausal hormone therapy (HT increases the risk of endometrial cancer, but less is known about the association with other types of HT. Using Cox proportional hazards regression, the authors examined the association of various types of HT with the risk of endometrial cancer among 115,474 postmenopausal women recruited into the European Prospective Investigation into Cancer and Nutrition between 1992 and 2000. After a mean follow-up period of 9 years, 601 incident cases of endometrial cancer were identified. In comparison with never users of HT, risk of endometrial cancer was increased among current users of estrogen-only HT (hazard ratio (HR = 2.52, 95% confidence interval (CI): 1.77, 3.57), tibolone (HR = 2.96, 95% CI: 1.67, 5.26), and, to a lesser extent, estrogen-plus-progestin HT (HR = 1.41, 95% CI: 1.08, 1.83), although risks differed according to regimen and type of progestin constituent. The association of HT use with risk was stronger among women who were older, leaner, or had ever smoked cigarettes. The finding of a strong increased risk of endometrial cancer with estrogenonly HT and a weaker association with combined HT supports the hypothesis that progestins have an attenuating effect on endometrial cancer risk. The increased risk associated with tibolone use requires further investigation.
KW - Endometrial neoplasms
KW - Estrogen replacement therapy
KW - Norpregnenes
KW - Postmenopause
KW - Prospective studies
UR - http://www.scopus.com/inward/record.url?scp=79952115034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952115034&partnerID=8YFLogxK
U2 - 10.1093/aje/kwq300
DO - 10.1093/aje/kwq300
M3 - Review article
C2 - 20961969
AN - SCOPUS:79952115034
SN - 0002-9262
VL - 172
SP - 1394
EP - 1403
JO - American journal of epidemiology
JF - American journal of epidemiology
IS - 12
ER -